TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03481842

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Linifanib
Description: in a minimally sufficient therapeutic dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBW2992
Description: in a minimally sufficient therapeutic dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib
Description: in a minimally sufficient therapeutic dose
Study: NCT05667883

Intervention type: DRUG
Intervention: glucocorticoid + cytoxan
Description: The initial full dose of prednisone was 1mg/kg/d (the maximum dose was 60mg/d) for 6-8 weeks, and then slowly decreased by 10% of the original dose every 1-2 weeks, and the later small dose was maintained at 0.4-0.5mg/kg/d; Cyclophosphamide 200mg/time, intravenous drip or oral every other day, up to the cumulative dose of 6-8g.

Intervention type: DRUG
Intervention: glucocorticoid + cytoxan
Description: The initial full dose of prednisone was 1mg/kg/d (the maximum dose was 60mg/d) for 6-8 weeks, and then slowly decreased by 10% of the original dose every 1-2 weeks, and the later small dose was maintained at 0.4-0.5mg/kg/d; Cyclophosphamide 200mg/time, intravenous drip or oral every other day, up to the cumulative dose of 6-8g.
Study: NCT05944159

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Study Group
Description: Study Group (n= 20) was recieved Temporomandibular joint ve soft tissue techniques. The techniques were applied 30 minutes once a week for 4 weeks by physiotherapist to the study group.

Intervention type: OTHER
Group type: OTHER
Intervention: Control Group
Description: Routin medication therapy was applied to the control group. Both groups were asked to do the home exercise program twice a day consisting of vestibular exercise videos sent over whatss app. It was questioned with a phone call once a week whether the exercises were done or not.
Study: NCT05464238

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise rehabilitation
Description: The initial phase of exercise training will be closely monitored and will be based on a three-weeks in-hospital stay to adjust and teach the exercise training which will be continued at home for 12 more weeks. In-hospital stays will be arranged country specific and hospitalization time may range. The rehabilitation program comprises of interval ergometer training (20 minutes 5 days per week), dumbbell training (30 minutes 5 days per week), respiratory therapy (30 minutes 5 days per week), mental training and guided walks for 2-5 times/week.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard treatment
Description: Standard treatment during study duration
Study: NCT04891575

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Control Intervention educational sessions
Description: The participant will attend 8 sessions that provide type 2 diabetes (T2D) and cardiovascular (CVD) risk reduction and lifestyle modification education focused on CVD and T2D risk factor reduction through promotion of participant self-management. Education will concentrate on healthy eating, physical activity, stress reduction, and other lifestyle risk reduction recommendations.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Dyad Intervention
Description: The participant and a co-participating family member will attend 8 sessions that provide type 2 diabetes (T2D) and cardiovascular (CVD) risk reduction and lifestyle modification education focused on CVD and T2D risk factor reduction through promotion of participant self-management. Education will concentrate on healthy eating, physical activity, stress reduction, and other lifestyle risk reduction recommendations.
Study: NCT05132387

Intervention type: OTHER
Intervention: ECMO assisted CPR in out-of-hospital cardiac arrest
Description: Patients included in the registry will be transferred during LUCAS assisted CPR by the Wroclaw Emergency Medical Services to the Emergency Department of the Wroclaw University Hospital where blood gasses will be assessed. If two or more of the following: end-tidal carbon dioxide (CO2) \> 10 mm Hg, arterial partial pressure of oxygen (PaO2) \>50 mm Hg or oxygen saturation \>85%, and lactic acid \<18 mmol/L will be fulfilled patient will be further transferred to the Cardiac Catheterization Laboratory for V-A ECMO implantation followed by coronary/pulmonary artery angiography and intervention.
Study: NCT05018195

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Excise adipose tissue
Description: Perform partial omentectomy to obtain one 5\*5 cm omental fat and excise one 3\*3 cm subcutaneous adipose tissue( 2 finger width above the pubic symphysis) during surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Excise adipose tissue
Description: Perform partial omentectomy to obtain one 5\*5 cm omental fat and excise one 3\*3 cm subcutaneous adipose tissue( 2 finger width above the pubic symphysis) during surgery
Study: NCT06351475

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intra-operative albumin administration
Description: Patients randomized in the intervention group (20% albumin + Ringer Lactate) will receive, during cytoreductive surgery with HIPEC, fluid therapy consisting in Ringer Lactate (based on a fluid management protocol specifically set up for the study, and based on latest recommendations) combined with 20% albumin. Patients randomized in the intervention group will receive a bolus of 3 mL/kg on one hour of 20% albumin from anesthetic induction . Dosage of albuminemia will be done 2 hours after the end of the bolus (target of 35-45 g/L of intra operative albuminemia). Then, infusion of 20% albumin (100 mL, 20g) will be administered for each 1200 mL of vascular filling by Ringer Lactate. Dosage of intra operative albuminemia will be realized 2 hours after the end of the bolus or infusion to ensure albuminemia is within the target concentrations (35-45 g/L). Use of 20% albumin will be realized for the entire duration of the surgery and stopped at the end of the surgery.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Ringer lactate
Study: NCT06206382

Intervention type: PROCEDURE
Intervention: Whipple operation
Description: Whipple operation is the surgery used for pancreatic head cancer in the form of pancreaticoduodenectomy then reconstruction

Intervention type: PROCEDURE
Intervention: Whipple operation
Description: Whipple operation is the surgery used for pancreatic head cancer in the form of pancreaticoduodenectomy then reconstruction
Study: NCT05296356

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OSU6162
Description: OSU6162
Study: NCT05097313

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Yeast β-glucan fiber
Description: The study is designed to determine if β-glucan is safe and if it presents an antioxidant and immunomodulatory response in healthy adults in Colombia.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Yeast β-glucan fiber
Description: The study is designed to determine if β-glucan is safe and if it presents an antioxidant and immunomodulatory response in healthy adults in Colombia.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral consumption of 200 mg (one capsule) or 400 mg (two capsules) of soy protein powder for 84 days.
Study: NCT06223243

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stingless bee honey mouthrinse
Description: Three bottles of 90ml of stingless bee honey of 20% concentration was given to each subject. This mouthrinse preparation was instructed for subjects to be taken 30ml each, thrice daily for three days.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: normal saline mouthrinse
Description: Subjects were instructed to rinse with 30ml of normal saline (0.9% concentration) thrice daily for three days.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: chlorhexidine mouthrinse
Description: Subjects were instructed to rinse with 30ml of chlorhexidine mouthrinse thrice daily for three days.
Study: NCT05840237

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anhydrous Enol-Oxaloacetate, a Medical Food
Description: Treatment with the medical food Oxaloacetate CFS, 2 - 500 mg capsules BID with food

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: White Rice Flour
Description: Treatment with the food White Rice Flour, 2- 500 mg capsules BID with food
Study: NCT05310162

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Food, fun and family
Description: The intervention consists of a series of change of habits in the way children eat, the reduction of the recreational time of screens and healthy habits of physical activity. This intervention, which is called Food, Fun \& Family (FFF), is aimed at parents and has been shown to be effective in reducing the consumption of empty calories by children. It teaches parents skills to reduce their daily energy intake of added sugars and saturated fats, it also seeks to reduce screen time.~The intervention contains information and recommendations, through guides, in which precise instructions are given about how to maintain a healthy environment at home.
Study: NCT06413095

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Intratumoral microdose injection by the CIVO device.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: MK-0482 + Pembrolizumab
Description: Intratumoral microdose injection by the CIVO device.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: MK-4830 + Pembrolizumab
Description: Intratumoral microdose injection by the CIVO device.
Study: NCT05398055

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin + Doxycycline
Description: azithromycin 500 mg orally every 24 hours for three dose plus doxycycline 100 mg orally every 12 hours for 7 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + Doxycycline
Description: doxycycline 100 mg orally every 12 hours for 7 days plus placebo 1 capsule every 24 hours, 3 doses
Study: NCT05607823

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Core Stabilization Training
Description: Core Stabilization training will be based on dynamic neuromuscular stabilization and consists of three stages. In the first session, it is to teach the simultaneous activation of the transversus abdominis, pelvic floor, multifidus and diaphragm muscles and to improve muscle coordination and proprioception in the entire spinal region. In the second and third phases, exercises will be made more intense to improve muscular endurance and stability. The difficulty of the exercises will be increased by working in different positions, using resistance bands, exercise balls and body weight, and adding movements to the extremities. A total of 10 sessions of treatment program will be applied to the patients for ten weeks, once a week.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Orofacial Manual Therapy
Description: As orofacial manual therapy, soft tissue (intraoral and extraoral trigger point therapy and myofascial release of painful muscles) and joint mobilization (caudal and ventro-caudal traction, ventral and mediolateral translation), muscle energy technique, fascia mandibularis release, occipital release and ligamentous treatment was planned.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Orofacial Manual Therapy
Description: As orofacial manual therapy, soft tissue (intraoral and extraoral trigger point therapy and myofascial release of painful muscles) and joint mobilization (caudal and ventro-caudal traction, ventral and mediolateral translation), muscle energy technique, fascia mandibularis release, occipital release and ligamentous treatment was planned.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional Physiotherapy
Description: Conventional physiotherapy consists of home exercise and patient education. Patient education consists of parafunctional behaviors, habits, a diet with soft food, and posture education. The exercises consist of exercises for the mandible, cervical and thoracic region and breathing. All movements are planned to be done at home 3 times a day, every day of the week.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional Physiotherapy
Description: Conventional physiotherapy consists of home exercise and patient education. Patient education consists of parafunctional behaviors, habits, a diet with soft food, and posture education. The exercises consist of exercises for the mandible, cervical and thoracic region and breathing. All movements are planned to be done at home 3 times a day, every day of the week.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional Physiotherapy
Description: Conventional physiotherapy consists of home exercise and patient education. Patient education consists of parafunctional behaviors, habits, a diet with soft food, and posture education. The exercises consist of exercises for the mandible, cervical and thoracic region and breathing. All movements are planned to be done at home 3 times a day, every day of the week.
Study: NCT05310162

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Counseling
Description: Simple verbal instructions will be given in the consultation to reduce the time of use of screens and refined sugar.~For refined sugar reduction, parents will be told to avoid sugary drinks, add sugar to drinks (juices, milk, etc.), and avoid snacks and sweets. It will also be indicated that the screen time should be less than two hours a day and in no case use them two hours before sleeping.
Study: NCT05375526

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magtrace
Description: In the proper ovarian ligament (or its remnants), close to the ovary and just below the peritoneum Magtrace® will be injected via a 12 Gauge (2mm) needle. This injection will be followed by an injection of 20 MBq 99mTc via the same 12 Gauge (2mm) needle.~If a hysterectomy has been conducted, this step can be omitted. In the infundibulopelvic ligament (suspensory ligament of the ovary), close to the ovary and just below the peritoneum Magtrace® will be injected via a 12 Gauge (2mm) needle. This injection will be followed by an injection of 20 MBq 99mTc via the same 12 Gauge (2mm) needle.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magtrace
Description: In the proper ovarian ligament (or its remnants), close to the ovary and just below the peritoneum Magtrace® will be injected via a 12 Gauge (2mm) needle. This injection will be followed by an injection of 20 MBq 99mTc via the same 12 Gauge (2mm) needle.~If a hysterectomy has been conducted, this step can be omitted. In the infundibulopelvic ligament (suspensory ligament of the ovary), close to the ovary and just below the peritoneum Magtrace® will be injected via a 12 Gauge (2mm) needle. This injection will be followed by an injection of 20 MBq 99mTc via the same 12 Gauge (2mm) needle.
Study: NCT05004558

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Remote-based Resistance Exercise Training
Description: All participants enrolled in the trial will receive supervised remote-based resistance exercise training. The exercises will be performed with the use of Therabands and will include 8-10 exercises performed for 1 set of 15 repetitions, performed 3 days per week for 24 weeks.
Study: NCT05673434

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TM4SF1-positive chimeric antigen receptor T-cell therapy
Description: Specification: 50mL/bag. Storage: The prepared CAR T-cells are cryopreserved in a preserving medium . This product is manufactured under the current good manufacture practices (cGMP) conditions, with restrictions on chemical components, free from animal- or human-derived components and confirming to the United States Pharmacopeia (USP)\<71\> and \<85\> regulations.~Preservation: The frozen CAR T-cells are preserved in the liquid nitrogen transfer tank.~Usage: The frozen CAR T-cells are preserved at low temperature and transferred to the bedside. The cells are thawed by 36 degrees centigrade to 38 degrees centigrade. water bath. The frozen cells are gently massaged until complete thawing. Then they are transfused back to the patients intravenously. The transfusion will be finished within 10-20 min.
Study: NCT04403789

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Time
Description: Employees will be provided with exercise time of 2 hours per week. The 2 hours should be used in two days. The intervention duration is 12 weeks.
Study: NCT05936593

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Condylar Stabilizing (CS) insert
Description: During TKA surgery a Condylar Stabilizing (CS) insert is implanted and tantalum beads are placed around the prosthesis.
Study: NCT05881486

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron 8mg
Description: 8 mg Ondansetron+100 ml normal saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosaprepitant 150 mg
Description: 150 mg fosaprepitant +100 ml normal saline
Study: NCT04850924

Intervention type: OTHER
Intervention: evaluation psychological trauma
Description: 9 classes of symptoms to be evaluated
Study: NCT05936593

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cruciate Retaining (CR) insert
Description: During TKA surgery a Cruciate Retaining (CR) insert is implanted and tantalum beads are placed around the prosthesis.
Study: NCT04910386

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Envafolimab plus Gemcitabine&Cisplatin
Description: Envafolimab a programmed death ligand immune check inhibitor Per Investigator decision

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine&Cisplatin
Description: The standard of care for the patients with unresectable/metastatic biliary tract cancer
Study: NCT04875468

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TheraCem self-adhesive resin cement
Description: MDP, calcium and fluoride releasing cement for dental zirconia crowns

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Multilink adhesive resin cement
Description: (non MDP, non-calcium and fluoride releasing cement)
Study: NCT05993988

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Muscle relaxing Technique
Study: NCT05587179

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: recovery position
Description: A side-lying recovery position is a first aid intervention that can be performed by laypeople when victims are unresponsive but breathing normally and, hence, do not require cardiopulmonary resuscitation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: recovery position
Description: A side-lying recovery position is a first aid intervention that can be performed by laypeople when victims are unresponsive but breathing normally and, hence, do not require cardiopulmonary resuscitation.
Study: NCT04760860

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Terazosin Hydrochloride
Description: In this double blind, randomized, placebo controlled phase I clinical trial, subjects randomized into the Terazosin group will receive Terazosin hydrochloride treatment for 15 weeks. Participants will start at 1mg daily for the first 6 week, then the dosage will be increased to 5mg daily over 3 weeks, and continued for the last 6 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: In this double blind, randomized, placebo controlled phase I clinical trial, subjects randomized into the control group will receive placebo for 15 weeks.
Study: NCT04916977

Intervention type: OTHER
Intervention: FD patients
Description: Patients with Fabry disease diagnosis
Study: NCT03851627

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone Undecanoate
Description: 1000mg/4ml i.m. initial, after 6 weeks, every 10 weeks thereafter

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Arm
Study: NCT04920084

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plant based meals
Description: For 12 weeks, patients will receive two premade meals per day, for lunch and dinner, prepared and shipped weekly by U.S.-based WFPBD company Plantable. The meals will have a low glycemic index and contain vegetables, whole grains, and plant-based fats that have undergone minimal processing. Instructions will be provided for food storage and reheating. Detailed recommendations for snacks and breakfasts meeting the standard of a WFPBD will also be given to supplement their daily calorie needs with access to an online portal from Plantable which contains education materials and access to a coach daily for 24 weeks.
Study: NCT05752097

Intervention type: DEVICE
Intervention: [18F]AlF-NOTA-FAPI-04 PET/CT examination
Description: The intravenous radiotracer dose is 1.85-2.59 MBq/kg, and imaging will be performed 50-60 min after radiotracer injection. All patients are required to urinate as much as possible for imaging preparations, which reduces the influence of the residual radiotracer in the renal pelvis and calyces. Some patients with poor renal function (GFR\<60 mL/min, urine volume \< 1000 mL/24 h) will be given diuretics (Furosemide, 0.57 mg/kg). The scope of the whole-body inspection is from the base of the skull to the base of the thigh, using five to six beds (3 min/bed). The matrix was 128×128, the PET layer thickness was 3 mm, and all PET images are reconstructed iteratively.

Intervention type: PROCEDURE
Intervention: Renal puncture biopsy
Description: The patients undergo renal puncture biopsy one day after PET/CT examination. Pathological results of renal biopsy will be collected after surgery, including but not limited to: pathological diagnosis, proportion of glomerulosclerosis, extent of inflammatory cell infiltration, and degree of renal interstitial fibrosis.
Study: NCT05382741

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab Injection for intravenous use 500 mg vial solution for infusion
Description: MEDI4736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib 30 mg capsules
Description: BAY73-4506
Study: NCT05088759

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Alert
Description: The alert-based CDS will consist of an on-screen electronic dialogue box that will notify the clinician that the patient is at increased risk for cardiovascular events and is not at LDL-C goal according to current evidence-based clinical practice guidelines. The clinician will have the opportunity to proceed to an order template through which ezetimibe or a PCSK9 inhibitor can be prescribed. The clinician could also elect to learn more about current evidence-based clinical practice guideline recommendations for LDL targets. Finally, the clinician could elect to proceed without ordering more intensive lipid-lowering therapy or reading the guidelines but would have to provide a rationale for not prescribing ezetimibe or a PCSK9 inhibitor.
Study: NCT01802541

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: diacylglycerol oil